Anish M. John - 24 Feb 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Reporting relationship: Chief Financial Officer
Issuer ticker: OCX
Reported as of: 24 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2023, 16:55:59 UTC
Prior SEC filing: 19 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Anish John

Key filing fact

Anish M. John filed Form 4 for Oncocyte Corp (OCX) on 28 Feb 2023.

Key facts

This page summarizes Anish M. John's Form 4 filing for Oncocyte Corp (OCX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2023, 16:55.

Change

Previous filing in this sequence was filed on 19 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCX transaction Derivative

Option to Purchase Common Stock

Award

Transaction value: $0
Shares: +121,381
Change %
Price: $0.000000
Shares after: 121,381
Date: 24 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 121,381
Exercise price: $0.3900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One third of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.